Compare Stocks → 348 million Americans lives to END as we know it? (From The Oxford Club) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:ANCNNASDAQ:CNATNASDAQ:KMPHOTCMKTS:PVOTF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.63+16.8%$0.65$0.50▼$1.95$6.72M1.6318,928 shs11,899 shsANCNAnchiano Therapeutics$0.73-18.1%$21.77$0.51▼$10.55$5.38M0.933.15 million shs423,449 shsCNATConatus Pharmaceuticals$0.20+25.0%$1.00$0.23▼$1.07$6.63M1.841.28 million shs735 shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsPVOTFBetterLife Pharma$0.13$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals+17.81%-2.81%+2.97%-41.59%-34.21%ANCNAnchiano Therapeutics-18.42%-0.06%-8.30%+22.88%-52.92%CNATConatus Pharmaceuticals+25.00%0.00%-60.00%-41.18%-75.85%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M2.07N/AN/A($2.27) per share-0.28ANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/ACNATConatus Pharmaceuticals$21.72M0.31N/AN/A$0.53 per share0.38KMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)ANCNAnchiano Therapeutics-$27.12M-$3.464.83N/AN/AN/A36.08%27.40%N/ACNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/APVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ALatest ADXS, PVOTF, ANCN, CNAT, and KMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/16/2024Q4 2023ADXSAyala PharmaceuticalsN/A-$2.96-$2.96-$2.96N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AANCNAnchiano TherapeuticsN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30ANCNAnchiano TherapeuticsN/A3.253.25CNATConatus PharmaceuticalsN/A16.2816.28KMPHZevra Therapeutics0.1410.1010.10PVOTFBetterLife PharmaN/A3.623.62OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ANCNAnchiano Therapeutics9.05%CNATConatus Pharmaceuticals15.20%KMPHZevra Therapeutics19.39%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ANCNAnchiano Therapeutics6.88%CNATConatus Pharmaceuticals11.30%KMPHZevra Therapeutics1.10%PVOTFBetterLife Pharma34.77%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableADXS, PVOTF, ANCN, CNAT, and KMPH HeadlinesSourceHeadline$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugsmsn.com - April 26 at 4:14 PMJardiance and Ofev propel Boehringer’s human pharma salesmsn.com - April 17 at 2:48 PMVertex Pharma scientist talks about the long road to developing non-addictive painkillersabcnews.go.com - April 15 at 12:36 PMPharmacy defends Eli Lilly off-label drug suitlifesciencesipreview.com - April 11 at 2:26 PMBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conferencetmcnet.com - April 11 at 9:26 AMVictory Over Big Pharma Will Take More Than the IRAmsn.com - April 4 at 8:20 PMLiberals Need to Be Radicalsprospect.org - April 4 at 10:19 AMPharma is betting big on connecting potential patients to its medications. It's just the beginningendpts.com - April 3 at 2:37 AMAEVIS VICTORIA SA - Fabrice Zumbrunnen to become…pharmiweb.com - March 13 at 4:50 AMPresence of Particulates Prompts Recall of Treprostinil Injectionempr.com - March 13 at 4:50 AMIn Vietnam’s Mekong Delta, the lure of moving to the city grows even stronger amid climate shockskdvr.com - March 12 at 10:24 PMAmerica’s Last Top Modelsnewyorker.com - March 12 at 10:24 PMProfile: Xi Jinping the reformerchinadaily.com.cn - March 12 at 12:23 PMBetterLife Pharma Inc.: BetterLife's 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton Universityfinanznachrichten.de - March 4 at 1:49 PMIndia continues fast economic growth but FDI falls sharplyglobal.chinadaily.com.cn - March 1 at 8:26 AMGenesisCare Completes Reorganisation and Emerges from Chapter 11pharmiweb.com - February 19 at 3:51 PMImmigrant Execs Give Back to OCocbj.com - February 5 at 9:25 PMThe tragedy of Leonard Farruku, the gifted young musician whose dream of a better life ended on the Bibby Stockholmtheguardian.com - February 5 at 9:25 PMWeight loss drugs could create the first $1 trillion pharma companiesmsn.com - February 1 at 9:57 AMRoff: Medicare prescription price controls will hurt seniorsnews-journal.com - January 31 at 11:57 PMBudget 2024 Live Updates: Infrastructure, income tax, fiscal deficit, job creation announcements expected from FM Sitharaman's Union Budgettimesofindia.indiatimes.com - January 31 at 11:57 PMBetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001finance.yahoo.com - January 2 at 10:19 AMBig Pharma scrambles to feed demand for weight-loss treatments amid rising U.S. obesity ratesnbcnewyork.com - November 16 at 5:01 PMBig Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity ratesmsn.com - November 16 at 12:01 PMMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Anchiano TherapeuticsNASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Conatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.BetterLife PharmaOTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.